CRNX as reported
Crinetics Pharmaceuticals, Inc. reported $42M of revenue over the trailing twelve months, +2928% on the year before. 8 reported series are charted on this page, each one as filed.
$42M
Revenue, trailing twelve months · to Q2 2026 · +2928% against the twelve months before
- Net Income
- −$502M
Net Income · +36% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$425M
Free Cash Flow · +37% year on year · trailing twelve months to Q2 2026
- Op Margin
- −25929%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $42M | +2928% | Q2 2026 |
| Net Income | −$502M | +36% | Q2 2026 |
| EPS | −$5.04 | +23% | Q2 2026 |
| Op Margin | −25929% | n/a | Q2 2026 |
| Net Margin | −23660% | n/a | Q2 2026 |
| ROE | −42% | n/a | Q2 2026 |
| ROA | −38% | n/a | Q2 2026 |
| Free Cash Flow | −$425M | +37% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Crinetics Pharmaceuticals, Inc. (CRNX) - Revenue & ProfitRevenue & ProfitCrinetics Pharmaceuticals, Inc. (CRNX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com